Learn More
Diagnostic Biosystems ROS1 ROS1
Supplier: Diagnostic Biosystems RMPD108

ROS1 rearrangements occur infrequently in lung ACA, however given the frequency of lung cancer in the population, ROS1-rearranged tumors represent a significant number of cancer patients. ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with response to the multitargeted tyrosine kinase inhibitor, crizotinib. ROS IHC can be readily incorporated into the diagnostic surgical pathology workup of lung adenocarcinoma, with results confirmed by FISH as needed.
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.